Page 1

EX - 99.1 2 d740262dex991.htm EX - 99.1 Exhibit 99.1 INTRA - CELLULAR THERAPIES REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE CAPLYTA supplemental new drug applications ( sNDAs ) for the treatment of bipolar depression in adults as both monotherapy and adjunctive treatment with lithium or valproate have been accepted for review by the FDA , with a PDUFA target action date of December 17 , 2021 . First quarter CAPLYTA total prescriptions ( TRx ) increased 23 % versus the previous quarter . Total revenues for the first quarter were $ 15.9 million . CAPLYTA achieved net product revenues of $ 15.6 million for the first quarter . Introduced ITI - 1284 ODT - SL , a deuterated form of lumateperone delivered sublingually as an orally disintegrating tablet . NEW YORK , May 10 , 2021 / GLOBE NEWSWIRE / — Intra - Cellular Therapies , Inc. ( Nasdaq : ITCI ) , a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system ( CNS ) disorders , today announced its financial results for the first quarter ended March 31 , 2021 and provided a corporate update . " The acceptance of our sNDAs by the FDA is an important step towards a potential new treatment option for patients living with bipolar depression , a condition with a limited number of approved treatments . While preparing for this significant opportunity , our team will continue to execute on our commercial objectives for CAPLYTA and advance our robust pipeline , " said Dr. Sharon Mates , Chairman and CEO of Intra - Cellular Therapies . 1